Gefitinib, erlotinib and afatinib are tyrosine kinase inhibitors (TKI) approved by the Food and Drug Administration (FDA) of the United States for treatment of patients with EGFR-mutated lung cancers [1–3]. This evidence concerns the gene EGFR and lung cancer.